Clinical trial
MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be…
NCT00112580 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00112580 |
|---|---|
| Title | MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery |
| Official title | Phase II Trial of Single Agent Ipilimumab (MDX-010 Anti CTLA-4) for Subjects With Locally Advanced or Metastatic Pancreatic Adenocarcinoma |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | ipilimumab |
| Enrollment | 27 |
| Start date | Jul 31, 2005 |
| Primary completion | Jun 30, 2009 |
| Completion | Jun 30, 2009 |
| First posted | Jun 3, 2005 |
| Last update posted | Sep 27, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: